This month’s update introduces several new drugs on the Canadian market:
- Myalepta (metreleptin) is a synthetic analog of the hormone leptin used to treat various forms of dyslipidemia.
- Sibboran (landiolol) is an ultra short-acting, β1-superselective intravenous adrenergic antagonist, which decreases the heart rate effectively with less negative effect on blood pressure or myocardial contractility.
- Uplizna (inebilizumab) is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults.